Aberrant activation of the PI3K/AKT signaling pathway at the translational level in response to ATRA or ATPR was revealed, and a sequential strategy including ATRA or ATPR plus a PI3K/AKT inhibitor was suggested as a potential treatment for AML. This evidence concerns the gene AKT1 and acute myeloid leukemia.